Goldman Sachs Lowers Estimates on Illumina | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Goldman Sachs today lowered estimates for Illumina following last week's pre-announcement of third-quarter revenues that fall short of Wall Street expectations.

In a research note, analyst Isaac Ro lowered estimates for 2012 through 2014 "as we take a more cautious view on HiSeq placements … consumable pull-through, MiSeq placements, and array growth."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.